A Phase I/II Study of AGA111 for Lumbar Interbody Fusion in Patients With Degenerative Disc Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

July 13, 2022

Study Completion Date

July 13, 2022

Conditions
Degenerative Disc Disease
Interventions
DRUG

AGA111

AGA111 is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.

DRUG

Placebo

Placebo is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.

Trial Locations (6)

100035

Beijing Jishuitan Hospital, Beijing

100191

Peking University Third Hospital, Beijing

215004

The Second Affiliated Hospital of Soochow University, Suzhou

215006

The First Affiliated Hospital of Soochow University, Suzhou

400016

The First Affiliated Hospital of Chongqing Medical University, Chongqing

510120

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou

Sponsors
All Listed Sponsors
lead

Angitia Biopharmaceuticals

INDUSTRY